Public Employees Retirement System of Ohio increased its position in Illumina, Inc. (NASDAQ:ILMN) by 43.5% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 117,380 shares of the life sciences company’s stock after buying an additional 35,602 shares during the period. Public Employees Retirement System of Ohio owned 0.08% of Illumina worth $32,783,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in ILMN. Kaizen Advisory LLC grew its holdings in Illumina by 161.0% during the second quarter. Kaizen Advisory LLC now owns 368 shares of the life sciences company’s stock valued at $103,000 after purchasing an additional 227 shares during the last quarter. Moneta Group Investment Advisors LLC grew its holdings in Illumina by 2,670.0% during the second quarter. Moneta Group Investment Advisors LLC now owns 9,695 shares of the life sciences company’s stock valued at $107,000 after purchasing an additional 9,345 shares during the last quarter. Sun Life Financial INC grew its holdings in Illumina by 152.5% during the second quarter. Sun Life Financial INC now owns 399 shares of the life sciences company’s stock valued at $111,000 after purchasing an additional 241 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. grew its holdings in Illumina by 3,192.3% during the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 428 shares of the life sciences company’s stock valued at $120,000 after purchasing an additional 415 shares during the last quarter. Finally, Hall Laurie J Trustee grew its holdings in Illumina by 189.5% during the second quarter. Hall Laurie J Trustee now owns 550 shares of the life sciences company’s stock valued at $154,000 after purchasing an additional 360 shares during the last quarter. Hedge funds and other institutional investors own 89.84% of the company’s stock.

Several brokerages have commented on ILMN. Deutsche Bank increased their price target on Illumina to $350.00 and gave the company a “buy” rating in a report on Friday. ValuEngine downgraded Illumina from a “strong-buy” rating to a “buy” rating in a report on Thursday. UBS Group started coverage on Illumina in a report on Tuesday. They set a “neutral” rating and a $340.00 price target on the stock. BidaskClub cut Illumina from a “strong-buy” rating to a “buy” rating in a research report on Thursday, October 4th. Finally, Piper Jaffray Companies increased their price objective on Illumina to $380.00 and gave the company an “overweight” rating in a research report on Tuesday, October 2nd. Five equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $324.76.

In related news, SVP Mostafa Ronaghi sold 10,000 shares of the firm’s stock in a transaction on Wednesday, October 10th. The stock was sold at an average price of $311.84, for a total value of $3,118,400.00. Following the completion of the transaction, the senior vice president now directly owns 80,805 shares of the company’s stock, valued at $25,198,231.20. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Robert S. Epstein sold 500 shares of the firm’s stock in a transaction on Monday, July 23rd. The stock was sold at an average price of $311.15, for a total value of $155,575.00. Following the completion of the transaction, the director now directly owns 6,139 shares of the company’s stock, valued at $1,910,149.85. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 52,483 shares of company stock valued at $17,702,063. 0.54% of the stock is owned by company insiders.

ILMN stock traded up $14.24 during midday trading on Friday, hitting $321.69. The stock had a trading volume of 1,856,939 shares, compared to its average volume of 891,778. The stock has a market cap of $53.96 billion, a P/E ratio of 80.42, a price-to-earnings-growth ratio of 3.04 and a beta of 0.97. Illumina, Inc. has a 52 week low of $198.21 and a 52 week high of $372.61. The company has a debt-to-equity ratio of 0.22, a current ratio of 2.74 and a quick ratio of 2.44.

Illumina (NASDAQ:ILMN) last issued its earnings results on Monday, July 30th. The life sciences company reported $1.43 EPS for the quarter, topping the consensus estimate of $1.11 by $0.32. The firm had revenue of $830.00 million during the quarter, compared to analysts’ expectations of $786.88 million. Illumina had a return on equity of 26.64% and a net margin of 20.88%. Illumina’s quarterly revenue was up 25.4% compared to the same quarter last year. During the same period last year, the business earned $0.82 earnings per share. Equities research analysts anticipate that Illumina, Inc. will post 5.46 EPS for the current year.

Illumina Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.

Further Reading: Calculate Your Return on Investment (ROI)

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.